Neville Rodie & Shaw Inc. Has $207,000 Holdings in Cigna Group $CI

Neville Rodie & Shaw Inc. trimmed its holdings in Cigna Group (NYSE:CI) by 73.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 718 shares of the health services provider’s stock after selling 1,969 shares during the period. Neville Rodie & Shaw Inc.’s holdings in Cigna Group were worth $207,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Flaharty Asset Management LLC acquired a new position in shares of Cigna Group in the 1st quarter valued at approximately $28,000. 1248 Management LLC acquired a new position in shares of Cigna Group in the first quarter valued at approximately $29,000. Solstein Capital LLC bought a new stake in shares of Cigna Group during the second quarter worth $29,000. Chilton Capital Management LLC acquired a new stake in shares of Cigna Group during the second quarter worth $30,000. Finally, Activest Wealth Management lifted its position in Cigna Group by 360.0% in the 1st quarter. Activest Wealth Management now owns 92 shares of the health services provider’s stock valued at $30,000 after acquiring an additional 72 shares in the last quarter. Institutional investors and hedge funds own 86.99% of the company’s stock.

Insider Activity

In other news, insider Brian C. Evanko sold 5,368 shares of the firm’s stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $300.00, for a total value of $1,610,400.00. Following the sale, the insider directly owned 51,182 shares in the company, valued at approximately $15,354,600. This trade represents a 9.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO David Cordani acquired 4,134 shares of Cigna Group stock in a transaction that occurred on Monday, November 3rd. The shares were purchased at an average price of $241.88 per share, for a total transaction of $999,931.92. Following the transaction, the chief executive officer directly owned 157,935 shares in the company, valued at $38,201,317.80. The trade was a 2.69% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.70% of the stock is owned by insiders.

Cigna Group Price Performance

NYSE:CI opened at $274.70 on Monday. Cigna Group has a 12-month low of $239.51 and a 12-month high of $350.00. The firm has a market capitalization of $73.38 billion, a price-to-earnings ratio of 12.12, a P/E/G ratio of 1.00 and a beta of 0.25. The stock’s 50 day moving average price is $280.44 and its two-hundred day moving average price is $293.90. The company has a quick ratio of 0.76, a current ratio of 0.76 and a debt-to-equity ratio of 0.74.

Cigna Group (NYSE:CI) last released its quarterly earnings data on Thursday, October 30th. The health services provider reported $7.83 EPS for the quarter, topping analysts’ consensus estimates of $7.64 by $0.19. Cigna Group had a net margin of 2.29% and a return on equity of 18.80%. The firm had revenue of $69.57 billion during the quarter, compared to analysts’ expectations of $66.40 billion. During the same period in the previous year, the business posted $7.51 earnings per share. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. Cigna Group has set its FY 2025 guidance at 29.600- EPS. On average, analysts anticipate that Cigna Group will post 29.77 earnings per share for the current year.

Cigna Group Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 18th. Investors of record on Thursday, December 4th will be given a dividend of $1.51 per share. This represents a $6.04 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Thursday, December 4th. Cigna Group’s dividend payout ratio (DPR) is currently 26.64%.

Analyst Upgrades and Downgrades

CI has been the topic of several recent research reports. Robert W. Baird dropped their price target on Cigna Group from $372.00 to $315.00 and set an “outperform” rating on the stock in a research note on Thursday. JPMorgan Chase & Co. dropped their target price on Cigna Group from $428.00 to $375.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 4th. Guggenheim reaffirmed a “buy” rating and set a $318.00 price target on shares of Cigna Group in a research report on Tuesday, December 2nd. Wells Fargo & Company cut their price objective on shares of Cigna Group from $354.00 to $300.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 5th. Finally, Sanford C. Bernstein decreased their target price on shares of Cigna Group from $346.00 to $294.00 and set a “market perform” rating for the company in a research report on Wednesday, November 12th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $331.77.

Cigna Group Company Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.